← Back to Search

Other

ADX-2191 for Retinitis Pigmentosa

Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

Summary

This trial involves injecting ADX-2191 directly into the eyes of patients with retinitis pigmentosa caused by specific genetic mutations. The goal is to improve or stabilize their vision by addressing the genetic issue directly in the eye.

Eligible Conditions
  • Retinitis Pigmentosa

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with adverse events (AEs)
Secondary study objectives
Assessment for change in central subfield foveal thickness and ellipsoid zone area/width
Central retinal sensitivity
Change in dark-adapted retinal sensitivity
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: ADX-2191 Three InjectionsExperimental Treatment1 Intervention
Group II: ADX-2191 Six InjectionsExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADX-2191
2022
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
32 Previous Clinical Trials
4,662 Total Patients Enrolled
~3 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top